Cargando…

The Clinical Presentations of Liver Abscess Development After Endoscopic Retrograde Cholangiopancreatography with Choledocholithiasis: A 17-Year Follow-Up

BACKGROUND: Endoscopic Retrograde Cholangiopancreatography (ERCP), used for choledocholithiasis treatment, carries a risk of pyogenic liver abscess (PLA) due to communication between the biliary system and bowel contents. However, limited data exists on this issue. This study aims to identify the ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, An-Che, Tai, Wei-Chen, Chiu, Shao-Ming, Sou, Fai-Meng, Yang, Shih-Cheng, Lu, Lung-Sheng, Kuo, Chung-Mou, Chiu, Yi-Chun, Chuah, Seng-Kee, Liang, Chih-Ming, Wu, Cheng-Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505383/
https://www.ncbi.nlm.nih.gov/pubmed/37724089
http://dx.doi.org/10.2147/IDR.S428125
_version_ 1785106908540043264
author Liu, An-Che
Tai, Wei-Chen
Chiu, Shao-Ming
Sou, Fai-Meng
Yang, Shih-Cheng
Lu, Lung-Sheng
Kuo, Chung-Mou
Chiu, Yi-Chun
Chuah, Seng-Kee
Liang, Chih-Ming
Wu, Cheng-Kun
author_facet Liu, An-Che
Tai, Wei-Chen
Chiu, Shao-Ming
Sou, Fai-Meng
Yang, Shih-Cheng
Lu, Lung-Sheng
Kuo, Chung-Mou
Chiu, Yi-Chun
Chuah, Seng-Kee
Liang, Chih-Ming
Wu, Cheng-Kun
author_sort Liu, An-Che
collection PubMed
description BACKGROUND: Endoscopic Retrograde Cholangiopancreatography (ERCP), used for choledocholithiasis treatment, carries a risk of pyogenic liver abscess (PLA) due to communication between the biliary system and bowel contents. However, limited data exists on this issue. This study aims to identify the risk factors pertaining to liver abscesses following ERCP lithotomy. METHODS: We conducted a retrospective case series across multiple centers to evaluate patients who developed PLA after ERCP for choledocholithiasis. Data was obtained from the Chung Gung Research Database (January 2001 to December 2018). Out of 220 enrolled patients, 195 were categorized in the endoscopic sphincterotomy (ES) group, while 25 were in the non-ES group for further analysis. RESULTS: The non-ES group had significantly higher total bilirubin levels compared to the ES group (4.3 ± 5.8 vs 1.9 ± 2.0, p<0.001). Abscess size, location, and distribution (single or multiple) were similar between the two groups. The most common pathogens were Klebsiella pneumoniae and Escherichia coli. Pseudomonas infection was significantly less prevalent in the ES group compared to the non-ES group (3.6% vs 16.7%, p=0.007). Patients with concurrent malignancies (HR: 9.529, 95% CI: 2.667–34.048, p=0.001), elevated total bilirubin levels (HR: 1.246, 95% CI: 1.062–1.461, p=0.007), multiple abscess lesions (HR: 5.146, 95% CI: 1.777–14.903, p=0.003), and growth of enterococcus pathogens (HR: 4.518, 95% CI: 1.290–15.823, p=0.001) faced a significantly higher risk of in-hospital mortality. CONCLUSION: PLA incidence was higher in the ES group compared to the non-ES group following ERCP for choledocholithiasis. Attention should be given to significant risk factors, including concurrent malignancies, elevated total bilirubin levels, multiple abscess lesions, and growth of enterococcus pathogens, to reduce in-hospital mortality.
format Online
Article
Text
id pubmed-10505383
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-105053832023-09-18 The Clinical Presentations of Liver Abscess Development After Endoscopic Retrograde Cholangiopancreatography with Choledocholithiasis: A 17-Year Follow-Up Liu, An-Che Tai, Wei-Chen Chiu, Shao-Ming Sou, Fai-Meng Yang, Shih-Cheng Lu, Lung-Sheng Kuo, Chung-Mou Chiu, Yi-Chun Chuah, Seng-Kee Liang, Chih-Ming Wu, Cheng-Kun Infect Drug Resist Original Research BACKGROUND: Endoscopic Retrograde Cholangiopancreatography (ERCP), used for choledocholithiasis treatment, carries a risk of pyogenic liver abscess (PLA) due to communication between the biliary system and bowel contents. However, limited data exists on this issue. This study aims to identify the risk factors pertaining to liver abscesses following ERCP lithotomy. METHODS: We conducted a retrospective case series across multiple centers to evaluate patients who developed PLA after ERCP for choledocholithiasis. Data was obtained from the Chung Gung Research Database (January 2001 to December 2018). Out of 220 enrolled patients, 195 were categorized in the endoscopic sphincterotomy (ES) group, while 25 were in the non-ES group for further analysis. RESULTS: The non-ES group had significantly higher total bilirubin levels compared to the ES group (4.3 ± 5.8 vs 1.9 ± 2.0, p<0.001). Abscess size, location, and distribution (single or multiple) were similar between the two groups. The most common pathogens were Klebsiella pneumoniae and Escherichia coli. Pseudomonas infection was significantly less prevalent in the ES group compared to the non-ES group (3.6% vs 16.7%, p=0.007). Patients with concurrent malignancies (HR: 9.529, 95% CI: 2.667–34.048, p=0.001), elevated total bilirubin levels (HR: 1.246, 95% CI: 1.062–1.461, p=0.007), multiple abscess lesions (HR: 5.146, 95% CI: 1.777–14.903, p=0.003), and growth of enterococcus pathogens (HR: 4.518, 95% CI: 1.290–15.823, p=0.001) faced a significantly higher risk of in-hospital mortality. CONCLUSION: PLA incidence was higher in the ES group compared to the non-ES group following ERCP for choledocholithiasis. Attention should be given to significant risk factors, including concurrent malignancies, elevated total bilirubin levels, multiple abscess lesions, and growth of enterococcus pathogens, to reduce in-hospital mortality. Dove 2023-09-13 /pmc/articles/PMC10505383/ /pubmed/37724089 http://dx.doi.org/10.2147/IDR.S428125 Text en © 2023 Liu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Liu, An-Che
Tai, Wei-Chen
Chiu, Shao-Ming
Sou, Fai-Meng
Yang, Shih-Cheng
Lu, Lung-Sheng
Kuo, Chung-Mou
Chiu, Yi-Chun
Chuah, Seng-Kee
Liang, Chih-Ming
Wu, Cheng-Kun
The Clinical Presentations of Liver Abscess Development After Endoscopic Retrograde Cholangiopancreatography with Choledocholithiasis: A 17-Year Follow-Up
title The Clinical Presentations of Liver Abscess Development After Endoscopic Retrograde Cholangiopancreatography with Choledocholithiasis: A 17-Year Follow-Up
title_full The Clinical Presentations of Liver Abscess Development After Endoscopic Retrograde Cholangiopancreatography with Choledocholithiasis: A 17-Year Follow-Up
title_fullStr The Clinical Presentations of Liver Abscess Development After Endoscopic Retrograde Cholangiopancreatography with Choledocholithiasis: A 17-Year Follow-Up
title_full_unstemmed The Clinical Presentations of Liver Abscess Development After Endoscopic Retrograde Cholangiopancreatography with Choledocholithiasis: A 17-Year Follow-Up
title_short The Clinical Presentations of Liver Abscess Development After Endoscopic Retrograde Cholangiopancreatography with Choledocholithiasis: A 17-Year Follow-Up
title_sort clinical presentations of liver abscess development after endoscopic retrograde cholangiopancreatography with choledocholithiasis: a 17-year follow-up
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505383/
https://www.ncbi.nlm.nih.gov/pubmed/37724089
http://dx.doi.org/10.2147/IDR.S428125
work_keys_str_mv AT liuanche theclinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup
AT taiweichen theclinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup
AT chiushaoming theclinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup
AT soufaimeng theclinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup
AT yangshihcheng theclinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup
AT lulungsheng theclinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup
AT kuochungmou theclinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup
AT chiuyichun theclinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup
AT chuahsengkee theclinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup
AT liangchihming theclinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup
AT wuchengkun theclinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup
AT liuanche clinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup
AT taiweichen clinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup
AT chiushaoming clinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup
AT soufaimeng clinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup
AT yangshihcheng clinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup
AT lulungsheng clinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup
AT kuochungmou clinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup
AT chiuyichun clinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup
AT chuahsengkee clinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup
AT liangchihming clinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup
AT wuchengkun clinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup